secwatch.observer — SEC 8-K summary
======================================

Issuer:     Seres Therapeutics, Inc. (MCRB)
CIK:        0001609809
Form:       8-K
Filed at:   2026-03-02T23:59:59+00:00
Accession:  0001193125-26-085368
Event type: leadership
Sentiment:  neutral
Materiality: 0.65
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Seres Therapeutics appoints Richard Kender as Interim CEO, effective March 2
----------------------------------------------------------------------------

- Thomas DesRosier and Marella Thorell step down as co-Presidents/co-CEOs but remain EVP CLO and EVP CFO.
- Kender receives $520K base salary, $250K signing bonus, and options for 200,000 shares.
- Matthew Henn named President (in addition to CSO); salary increased to $505K, $230K retention bonus.
- Kelly Brady promoted to EVP COO; salary $475K, $230K retention bonus, options for 75,000 shares.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1609809/000119312526085368/0001193125-26-085368-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1609809/000119312526085368/d13425d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-085368

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer